A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)

Summary

AZD2171 (cediranib maleate) may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying how well AZD2171 works in treating patients with refractory stage IV breast cancer

Timeline

Start

2005-09

Primary completion

2007-08

Completion

2007-12

Drugs

Indications